https://www.nytimes.com/2019/04/09/health/osteoporosis-evenity-bone-amgen.html
The Food and Drug Administration on Tuesday approved an osteoporosis drug, romosozumab (brand name Evenity), that restores bone without breaking it down, according to the findings of two large clinical trials. This breakthrough represents the first new treatment approach in nearly two decades, developed by Amgen, in collaboration with the Belgian drug company UCB. Read more!
Any questions or to speak to one of our doctors, please call 610-896-8400